Workflow
Electric Vertical Aircraft (EVA)
icon
Search documents
Blade(BLDE) - 2025 Q1 - Earnings Call Presentation
2025-05-12 11:17
Financial Highlights - FY 2024 revenue reached $249 million, showing a year-over-year growth of 10%[6] - Medical revenue for FY 2024 was $147 million, with a year-over-year growth of 16%[6] - Adjusted EBITDA improved by $178 million year-over-year in FY 2024[6] - Q1 2025 revenue was $54 million, reflecting a 10% year-over-year growth excluding Canada[6] - Passenger revenue in Q1 2025 was $18 million, showing a 42% year-over-year increase excluding Canada[6] - Adjusted EBITDA improved by $23 million year-over-year in Q1 2025[6] Medical Segment - Medical segment revenue for the trailing twelve months ending March 31, 2025, was $147 million, an 8% year-over-year growth[11] - Medical segment adjusted EBITDA for the same period was $19 million, with a 25% year-over-year growth[11] - Flight Profit for the medical segment was $33 million, with a 22% margin and 25% year-over-year growth[11] Passenger Segment - Passenger segment revenue for the trailing twelve months ending March 31, 2025, was $105 million, a 10% year-over-year growth, or 42% excluding Canada[11] - Passenger segment adjusted EBITDA for the same period was $63 million, with a $109 million growth year-over-year[11] - Flight Profit for the passenger segment was $28 million, with a 27% margin and 48% year-over-year growth[11] Organ Transplant - From 2018 to 2024, heart, liver, and lung transplant distances increased by 64%[42] Ground Transport - Blade Medical's ground transport annualized revenue is approximately $20 million[50]